bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s What Happened

Shares of bioMerieux (OTCMKTS:BMXMF) gapped down prior to trading on Monday . The stock had previously closed at $82.78, but opened at $78.31. bioMerieux shares last traded at $78.31, with a volume of 58 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Piper Sandler began coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Five analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, bioMerieux currently has a consensus rating of “Reduce”.

bioMerieux Stock Down 5.4%

The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48. The stock has a fifty day moving average price of $82.13 and a two-hundred day moving average price of $102.95.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.